Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
NEW YORK, Sept. 06, 2016 -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the following investor conferences:
- The 23rd Annual NewsMakers in the Biotech Industry Conference in New York City on Friday, September 9, 2016 at 3:30 PM Eastern Time.
- The Rodman & Renshaw 18th Annual Global Investment Conference in New York City on Tuesday, September 13, 2016 at 4:40 PM Eastern Time.
Live webcasts and archives of the events can be viewed on the Investors section of the Company's website at www.axsome.com.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, including pain, for which there are limited existing treatment options. Axsome’s product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05. AXS-02 is currently in Phase 3 trials in complex regional pain syndrome (CRPS) and knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) with an additional Phase 3 trial planned in chronic low back pain (CLBP) associated with Modic changes (MCs). AXS-05 is currently in a Phase 3 trial in treatment resistant depression (TRD), and a Phase 2/3 trial in agitation in patients with Alzheimer’s disease (AD) is planned. AXS-02 and AXS-05 are investigational product candidates not approved by the FDA. For more information, please visit the company website at www.axsome.com. The company may occasionally disseminate material, nonpublic information on the company website.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
Axsome Contact: Mark Jacobson Vice President, Operations Axsome Therapeutics, Inc. 25 Broadway, 9th Floor New York, NY 10004 Tel: 212-332-3243 Email: [email protected] www.axsome.com Trout Group Contact: Marcy Beth Nanus Senior Vice President The Trout Group LLC Tel: 646-378-2927 Email: [email protected]
